The authors discovered that targeting EphA2 suppressed both AKT and JAK1/STAT3 signaling, two separate oncogenic pathways in hepatocelllar carcinoma.
[Cell Reports]
Wang, H., Hou, W., Perera, A., Bettler, C., Beach, J. R., Ding, X., Li, J., Denning, M. F., Dhanarajan, A., Cotler, S. J., Joyce, C., Yin, J., Ahmed, F., Roberts, L. R., & Qiu, W. (2021). Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling. Cell Reports, 34(8). https://doi.org/10.1016/j.celrep.2021.108765 Cite
0